The observation that patients with high IL1RL1 expression exhibit lower survival rates in comparison to those with low IL1RL1 expression prompted us to investigate its expression in different molecular genetic subtypes of leukemia such as MLL-AF9 fusion. This evidence concerns the gene KMT2A and leukemia.